To the Editor.—
The reports by Van Putten et al1 and Levinson et al2 in the August 1990 issue of the Archives extend our knowledge of the appropriate dosages for neuroleptic medications in the treatment of psychotic illnesses.There are some unanswered questions that I hope the authors can address in greater detail. In both reports, the populations studied were largely black. This could provide specific answers to important treatment issues related to black patients diagnosed as schizophrenic. For instance, it has been reported that black patients respond to neuroleptic medications differently than white patients do.3 It has also been suggested that black patients may be misdiagnosed as schizophrenic at a significantly higher rate than white patients do. Jones and Gray4 say that this occurs primarily in black patients with bipolar disorders who are misdiagnosed as schizophrenic.Given these findings, were there significant racial differences in treatment
Stephen AM. Blacks, Schizophrenia, and Neuroleptic Treatment. Arch Gen Psychiatry. 1992;49(2):164–165. doi:10.1001/archpsyc.1992.01820020084013
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: